Search Results

You are looking at 71 - 80 of 1,650 items for :

  • "chemotherapy" x
Clear All
Full access

Emil Lou, Donna D'Souza and Andrew C. Nelson

carcinoembryonic antigen (CEA) biomarker while on combination chemotherapy (FOLFIRI with bevacizumab), bevacizumab was discontinued in favor of initiating an EGFR inhibitor (panitumumab) while continuing the FOLFIRI backbone. This alteration to her treatment

Full access

Mary F. Mulcahy and Al B. Benson III

single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study . Ann Oncol 1998 ; 9 : 105 – 108 . 13 Becouarn Y Ychou M Ducreux M . Phase II trial of oxaliplatin as first-line chemotherapy in metastatic

Full access

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. Miyata, Martin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt and Michael K. Wong

Web site at www.nccn.org .) These guidelines are also available on the Internet. For the latest update, please visit www.nccn.org . References 1 Dale DC McCarter GC Crawford J . Myelotoxicity and dose intensity of chemotherapy

Full access

Matthieu Picard, Ursula A. Matulonis and Mariana Castells

Ovarian cancer is the leading cause of death among gynecologic malignancies and ranks fifth in overall cancer-related mortality among women in the United States. 1 Chemotherapy, particularly with a taxane and platinum combination, is key to

Full access

Gary H. Lyman

Dr. Lyman has disclosed that he receives research grant support from Amgen Inc. References 1 Crawford J Dale DC Kuderer NM . Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of

Full access

Rosalyn A. Juergens and Julie R. Brahmer

CP . Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer . N Engl J Med 2002 ; 346 : 92 – 98 . 4. Sandler AB Gray R Brahmer J . Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or

Full access

Pankaj Singhal and Shashikant Lele

58 . 14. Kirmani S Braly PS McClay EF . A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer . Gynecol Oncol 1994 ; 54 : 338 – 344 . 15. Alberts DS Liu PY Hannigan EV

Full access

Peyman Haghighat and Tanios Bekaii-Saab

chemotherapy plus best supportive care with best supportive care in advanced gastric cancer . Ann Oncol 1997 ; 8 : 163 – 168 . 5. MacDonald JS Schein PS Woolley PV . 5-fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for

Full access

Daniel Morgensztern and Ramaswamy Govindan

. 7. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group . BMJ 1995 ; 311 : 899 – 909 . 8. Scagliotti

Full access

Robert McNulty

in oncology: update 2006 . J Clin Oncol 2006 ; 24 : 2932 – 2946 . 3. Cancer Care Ontario: use of 5-HT3 receptor antagonists in patients receiving moderately or highly emetogenic chemotherapy , 2003 . Available at: http